News

Jan 14, 2026

New Partnership: Scaling our impact in Canada

We’re pleased to share that Neurim Pharmaceuticals has signed an exclusive licensing and distribution agreement with KYE Pharmaceuticals Inc. to bring SLENYTO® (Extended-release melatonin) to the Canadian market.
This partnership marks a significant milestone in our global expansion, ensuring that more Canadian children living with Autism Spectrum Disorder (ASD) and Smith-Magenis Syndrome (SMS), supporting better sleep and improved quality of life
Read the full press release here: https://lnkd.in/eej-6wyf